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TRANSLATIONAL SCIENCES
Glycoproteomic Analysis of the Aortic 
Extracellular Matrix in Marfan Patients
Xiaoke Yin (殷晓科),* Shaynah Wanga,* Adam L. Fellows, Javier Barallobre-Barreiro, Ruifang Lu, Hongorzul Davaapil, Romy Franken, 
Marika Fava, Ferheen Baig, Philipp Skroblin, Qiuru Xing, David R. Koolbergen, Maarten Groenink, Aeilko H. Zwinderman,  
Ron Balm, Carlie J.M. de Vries, Barbara J.M. Mulder, Rosa Viner, Marjan Jahangiri, Dieter P. Reinhardt, Sanjay Sinha,  
Vivian de Waard,† Manuel Mayr†
OBJECTIVE: Marfan syndrome (MFS) is caused by mutations in FBN1 (fibrillin-1), an extracellular matrix (ECM) component, 
which is modified post-translationally by glycosylation. This study aimed to characterize the glycoproteome of the aortic ECM 
from patients with MFS and relate it to aortopathy.
APPROACH AND RESULTS: ECM extracts of aneurysmal ascending aortic tissue from patients with and without MFS were enriched 
for glycopeptides. Direct N-glycopeptide analysis by mass spectrometry identified 141 glycoforms from 47 glycosites within 
35 glycoproteins in the human aortic ECM. Notably, MFAP4 (microfibril-associated glycoprotein 4) showed increased and 
more diverse N-glycosylation in patients with MFS compared with control patients. MFAP4 mRNA levels were markedly 
higher in MFS aortic tissue. MFAP4 protein levels were also increased at the predilection (convexity) site for ascending 
aorta aneurysm in bicuspid aortic valve patients, preceding aortic dilatation. In human aortic smooth muscle cells, MFAP4 
mRNA expression was induced by TGF (transforming growth factor)-β1 whereas siRNA knockdown of MFAP4 decreased 
FBN1 but increased elastin expression. These ECM changes were accompanied by differential gene expression and protein 
abundance of proteases from ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family and their 
proteoglycan substrates, respectively. Finally, high plasma MFAP4 concentrations in patients with MFS were associated with 
a lower thoracic descending aorta distensibility and greater incidence of type B aortic dissection during 68 months follow-up.
CONCLUSIONS: Our glycoproteomics analysis revealed that MFAP4 glycosylation is enhanced, as well as its expression during 
the advanced, aneurysmal stages of MFS compared with control aneurysms from patients without MFS.
VISUAL OVERVIEW: An online visual overview is available for this article.
Key Words: elastin ◼ extracellular matrix ◼ glycoproteins ◼ Marfan syndrome ◼ proteomics
Marfan syndrome (MFS) is an autosomal genetic disease, with at least 90% of patients exhibiting mutations within the gene encoding for the extra-
cellular matrix (ECM) glycoprotein fibrillin-1 (FBN1).1 In 
the aorta, FBN1 is linked to vascular smooth muscle cells 
(SMCs) by integrins as well as within elastin microfibrils 
within the ECM.2,3 FBN1 mutations are either haploinsuf-
ficient or dominant negative, which seems to influence 
the MFS phenotype.1 In addition to aneurysms, aortic 
dissections constitute a significant number of life-threat-
ening events in patients with MFS.4 While dissections of 
the ascending aorta (type A) are largely prevented by 
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aggressive prophylactic aortic surgery, the dissections of 
the thoracic descending aorta (type B) usually present 
asymptomatically later in life, at an aortic diameter far 
below the 4.5 cm cutoff value for surgery.5
One proposed mechanism involved in MFS aorto-pathy 
is the function of FBN1 as a regulator of TGF-β (trans-
forming growth factor β) bioavailability, whereby defective 
FBN1 production leads to heightened TGF-β signaling and 
eventual aortic dilatation and aneurysms in mice. However, 
clinical studies showed that losartan had no superior thera-
peutic effect, when compared with or used as an additive to 
standard β-blocker administration in undifferentiated MFS 
cohorts.6–8 Thus, a better understanding of the downstream 
consequences of defective FBN1 on ECM remodeling that 
leads to the structural failure of the vessel wall in MFS is 
required. ECM remodeling may involve the canonical func-
tion of FBN1 in elastic fiber synthesis and cross-linking9 as 
well as post-translational modifications (PTMs) that regu-
late the function of ECM proteins.
Given that MFS results in high mortality because of 
aortopathy, a strong focus has been on elastin and col-
lagen, the 2 predominant ECM components governing 
the structural integrity of the vascular wall.3 MFS aortas 
display not only abnormal organization and metabolism 
of collagen and elastin fibers with an abnormal appear-
ance of microfibrils10 but also a significant component of 
ECM degradation,11,12 as confirmed using 3-dimensional 
confocal imaging and atomic force microscopy.13
Interestingly, mutations in FBN1 causing MFS include 
those affecting PTMs of the protein, for example, the gen-
eration of an extra N-glycosylation site on FBN1.14 Aber-
rant glycosylation of proteins alters their folding, solubility, 
binding, and degradation.15 Interestingly, a large proportion 
of ECM proteins contain glycosylation sites, and the glyco-
sylation profiles of FBN1 and other ECM constituents could, 
therefore, be relevant to the pathology of MFS. Given the 
technical challenges associated with the study of glycosyl-
ation, this key PTM has long been neglected. Only recent 
advances in glycoproteomics have made it feasible to directly 
analyze glycopeptides using mass spectrometry (MS).16,17 
Over recent years, we have developed extraction methods to 
enrich for ECM proteins in cardiovascular tissues18 that are 
also amenable for direct analysis of glycosylation by MS.19
In the present study, we have applied this MS method 
to analyze the ECM glycoproteome in thoracic aortic aneu-
rysms from patients with and without MFS. For the first time, 
we demonstrate aberrant glycosylation alongside elevated 
levels of the FBN1-interacting MFAP4 (microfibril-associ-
ated glycoprotein 4) in MFS and provide evidence for the 
application of MFAP4 as a potential plasma biomarker to 
identify patients with MFS at risk for type B aortic dissection.
MATERIALS AND METHODS
The data that support the findings of this study are available 
from the corresponding author upon reasonable request.
Sample Collection From Patients With MFS
For glycoproteomic analysis, aortic aneurysmal tissue was col-
lected during surgery from 11 patients with MFS and 6 patients 
without MFS who had undergone aortic root and ascending 
aorta replacement (Table I in the online-only Data Supplement). 
Nonstandard Abbreviations and Acronyms
ADAMTS  a disintegrin and metalloprotein-
ase with thrombospondin motifs
ALKi  activin receptor-like kinase 4,5,7 
inhibitor
BAV bicuspid aortic valve
CSPG2 or VCAN  chondroitin sulfate proteoglycan 
2 or versican
ECM extracellular matrix
ETD electron transfer dissociation
FBN1 fibrillin-1
GuHCl guanidine hydrochloride
HCD  higher-energy collisional 
dissociation
iPSC induced pluripotent stem cell
LC-MS/MS  liquid chromatography-tandem 
mass spectrometry
MFAP4  microfibril-associated glycopro-
tein 4
MFS Marfan syndrome
PGCA or ACAN  chondroitin sulfate proteoglycan 
1 or aggrecan 
PTMs post-translational modifications
qPCR  quantitative polymerase chain 
reaction
SMCs smooth muscle cells
TAV tricuspid aortic valve
TGF-β transforming growth factor β
Highlights
• Glycoproteomic analysis revealed enhanced MFAP4 
(microfibril-associated glycoprotein 4) levels in the 
extracellular matrix of the ascending aorta from 
patients with Marfan syndrome compared to aneu-
rysm patients without Marfan syndrome.
• Silencing MFAP4 expression in aortic smooth mus-
cle cells had a profound impact on the expression 
of elastin and fibrillin-1, as well as ADAMTS (a dis-
integrin and metalloproteinase with thrombospondin 
motifs) proteases.
• High levels of plasma MFAP4 might be associ-
ated with reduced distensibility of the descending 
aorta and predict the probability of a type B aortic 
dissection.
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Of the 6 patients without MFS, 3 had a known mutation, namely 
for TGF-β receptor type-1 (TGFBR1), elastin (ELN), and aortic 
smooth muscle actin (ACTA2). No mutation was found for the 
other 3 patients based on current mutation screening. A local 
Research Ethics Committee gave approval for the use of these 
samples when used anonymously (Ref number W16_037 no. 
16.052). For plasma analysis, the same patients with MFS, who 
were from a subset of the COMPARE trial (Cozaar in Marfan 
Patients Reduces Aortic Enlargement; NTR1423)20 and included 
in a study on plasma TGF-β1 in aortic disease,21,22 were used to 
measure plasma MFAP4 concentration. Inclusion criteria of the 
COMPARE trial were the diagnosis of MFS was according to the 
Ghent criteria23 relevant at the time and an age of >18 years. The 
exclusion criteria were angiotensin-converting enzyme inhibitor 
usage and previous replacement of more than one part of the 
aorta. However, in this substudy, all patients were included irre-
spective of the medication they used, and patients with prior aor-
tic surgery were also allowed.20 At the time of inclusion, plasma 
samples (n=96) from patients with MFS were obtained, and aor-
tic root diameters were measured. Written consent was obtained 
from all patients included in this study.
ECM Extraction From Aortic Tissue
Human aortic tissues were diced into small pieces and subjected 
to our 3-step extraction.18 First, the tissues were incubated in a 
sodium chloride (NaCl, 10X volume: weight, ie, 10 µL per 1 mg) 
buffer (0.5 mol/L NaCl, 10 mmol/L Tris, pH=7.5, 25 mmol/L 
EDTA, supplemented with Protease Inhibitor Cocktail from 
Sigma, P8340), with slow agitation for 4 hours. The NaCl frac-
tion was transferred into a new tube and kept at −80°C for later 
use. Subsequently, the tissues were decellularized by incubation 
in a sodium dodecyl sulphate (SDS, 10X volume: weight) buffer 
(0.08% SDS, 25 mmol/L EDTA, supplemented with Proteinase 
Inhibitor Cocktail) with slow agitation for 4 hours. The SDS frac-
tion was transferred into a new tube and kept at −80°C for later 
use. Finally, the samples were incubated in a guanidine hydro-
chloride (GuHCl, 5X volume: weight) buffer (4 mol/L GuHCl, 
50 mmol/L sodium acetate, pH=5.8, 25 mmol/L EDTA supple-
mented with Protease Inhibitor Cocktail) with vigorous agitation 
for 48 hours. The GuHCl fraction was recovered and stored at 
−80°C for later use. Protein concentrations of NaCl and GuHCl 
fractions were estimated using Nanodrop spectrophotometer 
(ND-1000, Thermo Fisher Scientific) at 280 nm.
Glycopeptide Enrichment
One hundred micrograms of protein from the GuHCl fraction 
per sample were precipitated using 100% ethanol overnight at 
−20°C. After centrifugation at 14000g for 30 minutes at 4°C, 
the pellets were briefly dried using a SpeedVac (Thermo Fisher 
Scientific, Savant SPD131DDA) and resuspended in 0.1% SDS, 
50 mmol/L Tris-HCl, pH=8.8. After reduction with 10 mmol/L 
dithiothreitol at 37°C for 1 hour, 240 rpm, the samples were 
cooled down to room temperature before being alkylated by 50 
mmol/L iodoacetamide in the dark for 1 hour. Prechilled (−20°C) 
acetone (8× volume) was used to precipitate the samples over-
night at −20°C. Samples were centrifuged at 14000g for 30 min-
utes at 4°C and the supernatant subsequently discarded. Protein 
pellets were briefly dried using SpeedVac and resuspended in 
100 µL of 0.1 mol/L triethylammonium bicarbonate (pH=8.2) 
then digested with 2 µg of trypsin (MS Grade, TPCK-treated to 
eliminate chymotryptic activity, Thermo Fisher Scientific) at 37°C 
overnight. Peptides were labeled with Tandem Mass Tag zero 
reagent (TMT0, Thermo Scientific Scientific) following the manu-
facturer’s instructions. Labeled peptides were further enriched for 
glycopeptides using zwitterionic hydrophilic interaction liquid chro-
matography resin (ZIC-HILIC, Merck, 72103-3).17 Glycopeptide 
fractions were dried using SpeedVac and resuspended in 5% 
acetonitrile, 0.1% trifluoroacetic acid in H2O.
Glycoproteomics Analysis
The glycopeptide enriched fraction was separated using the 
EASY-nLC liquid chromatography (LC) system (Thermo Fisher 
Scientific) with a Magic C18 spray tip 15 cm×75 µm column 
(Bruker-Michrom, Auburn, CA). Peptides were eluted using 4% 
to 30% acetonitrile, 0.1% formic acid within 1 hour at a flow 
rate of 300 nL/min and directly analyzed with an Orbitrap Elite 
hybrid MS (Thermo Fisher Scientific) with electron transfer disso-
ciation (ETD). Two MS/MS methods were used. For the alternat-
ing higher-energy collisional dissociation (HCD) and ETD MS/
MS (HCD-alt-ETD) method, the top 10 ions were analyzed via 
HCD and ETD. For the HCD product-dependent ETD (HCD-
pd-ETD) method, the top 10 ions were analyzed via HCD, and 
product-dependent ETD acquisition was triggered by product 
(oxonium) ions (m/z 163.0812 for hexose; m/z 204.0864 and 
138.0554 for N-acetyl-hexosamine and its fragment ion, respec-
tively). Glycopeptides were identified using Byonic software (ver-
sion 2.9.30, Proteome Metrics).17 Identified glycoforms were 
quantified using Pinnacle software (version 1.0.65.0, Optys Tech 
Corporation, Boston, MA). The precursor peak area was used for 
quantification and normalized to the total ion current. The 2 MS 
runs from the same sample using different fragmentation meth-
ods were used as technical replicates for quantitation.
Proteomics Analysis of Aortic Samples From 
Patients With Bicuspid Aortic Valve
Aortic samples from bicuspid aortic valve (BAV) patients and 
tricuspid aortic valve (TAV) patients were collected during aor-
tic surgery at St George’s Hospital (London, UK). All proce-
dures were approved by the Regional Ethics Committee Board 
(London, REC number 08/H0803/257). The diagnosis of BAV 
was confirmed by direct visualization of the valve phenotype. 
For each patient, 2 aortic specimens were collected, one from 
the concave area and one from the convex area of the ascend-
ing aorta and immediately frozen at −80°C for proteomic analy-
sis (Table II in the online-only Data Supplement). The samples 
were anonymized directly after surgery and before the experi-
mental procedure and analysis.
ECM proteins were extracted using the same method as 
described above. Twenty micrograms of proteins from GuHCl 
fractions were precipitated in 100% ethanol, and the pellets were 
resuspended in deglycosylation buffer (0.2 mol/L Tris, 0.2 mol/L 
sodium acetate, 0.1 mol/L EDTA, 50 mmol/L sodium phos-
phate, pH=6.8). The following deglycosylation enzymes were 
used: endo-α-N-acetylgalactosaminidase, β1,4-galactosidase, 
β-N-acetylglucosaminidase, α-2-3,6,8,9-Neuraminidase (all from 
Merck-Millipore Glycoprotein Deglycosylation Kit, 362280), 
Chondroitinase ABC (Sigma-Aldrich, C3667), Heparinase II 
(Sigma-Aldrich, H6512), and Endo-β1,4-galactosidase (Sigma-
Aldrich, G6920). Samples were incubated for 1 hour at 25°C, 
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followed by 24 hours at 37°C in agitation then dried using 
SpeedVac. Subsequently, samples were reconstituted in O18 
water containing N-Glycosidase F (PNGase F, from the Merck-
Millipore Glycoprotein Deglycosylation Kit, 362280) and incu-
bated at 37°C with agitation for 24 hours.
After deglycosylation, proteins were denatured using 6 
mol/L urea, 2 mol/L thiourea, reduced with 10 mmol/L dithio-
threitol, and alkylated with 50 mmol/L iodoacetamide. Proteins 
were precipitated by prechilled acetone overnight, resuspended 
in 0.1 mol/L triethylammonium bicarbonate and digested with 
0.4 µg trypsin overnight. The digestion was stopped by using 
1% trifluoroacetic acid. Peptide samples were purified using 
a 96-well C18 spin plate (Harvard Apparatus). The eluates 
were frozen at −80°C for 2 hours before being immediately 
lyophilized (Christ Alpha 1–2 LD plus) at −55°C overnight. The 
peptides of BAV samples were reconstituted with 2% ace-
tonitrile, 0.05% trifluoroacetic acid in H2O, and separated on 
a nanoflow LC system (UltiMate 3000 RSLCnano). Samples 
were injected onto a trap column (Acclaim PepMap100 C18 
Trap, 5 mm×300 µm) at a flow rate of 25 µL/min for 3 minutes, 
using 2% acetonitrile, 0.1% formic acid in H2O. The following 
LC gradient was then used to separate the peptides at 300 nL/
min: 0 to 10 minutes, 2% to 10% B; 10 to 200 minutes, 10% 
to 30% B; 200 to 210 minutes, 30% to 40% B; 210 to 220 
minutes, 99% B, 220 to 240 minutes 2% B, where A=0.1% 
formic acid in H2O, B=80% acetonitrile, 0.1% formic acid in 
H2O. The reverse phase column (Acclaim PepMap100 C18, 
50 cm×75 µm) was set at 40°C and coupled to a nanospray 
source (Picoview, New Objective, US). Spectra were collected 
from a Thermo Q Exactive HF Mass Spectrometer (QE HF MS, 
Thermo Fisher Scientific) using full MS mode over the mass-
to-charge (m/z) range 350 to 1600. Data-dependent MS/MS 
scan was performed on the most abundant 15 ions in each full 
MS scan with dynamic exclusion enabled.
Proteome Discoverer (version 2.2.0.388, Thermo Fisher 
Scientific) was used to search raw data files against the human 
database (UniProtKB/Swiss-Prot version 2018_05, 20349 
protein entries) using Mascot (version 2.6.0, Matrix Science). 
The mass tolerance was set at 10 ppm for precursor ions and 
20 mmu for fragment ions. Trypsin was used as the enzyme 
with 2 missed cleavages being allowed. Carbamidomethylation 
of cysteine was chosen as a fixed modification; oxidation of 
methionine, lysine and proline, and deamidation of aspara-
gine in the presence of O18 water were chosen as variable 
modifications. Scaffold (version 4.8.7, Proteome Software Inc, 
Portland, OR) was used to validate MS/MS-based peptide and 
protein identifications with the following filters: a peptide prob-
ability of >95.0%, a protein probability of >99.0%, and at least 
2 independent peptides per protein. The normalized total ion 
current was used for quantification.24
Selected proteins were quantified in the BAV samples, as 
well as TAV samples, using multiple reaction monitoring on an 
UltiMate 3000 RSLCnano system with the same setup, cou-
pled to a triple quadrupole MS (TSQ Vantage, Thermo Fisher 
Scientific). The TSQ Vantage was set in positive ion mode with 
ion transfer capillary temperature at 275°C and spray voltage 
at 3200 V. Both Q1 and Q3 were set at unit mass resolution 
(0.7Th FWHM), and argon was used as the collision gas at 1.0 
mTorr. For the scheduled multiple reaction monitoring method, 
a retention time window of 8 minutes and a cycle time of 1.43 
seconds were used. Skyline software (version 3.1, MacCoss 
Lab Software) was used to generate the transition list with pre-
dicted collision energies as well as optimized transitions (Table 
XI in the online-only Data Supplement). Multiple reaction moni-
toring data were analyzed by Skyline. All peaks were reviewed 
and integrated manually. Total fragment peak areas were used 
for quantification.
Immunoblotting
Proteins from the GuHCl and NaCl fractions were precipitated 
in 100% ethanol or acetone, respectively, overnight at −20°C 
and deglycosylated as described in BAV sample preparation 
method, except that PNGase F was added in parallel to the other 
enzymes, and the incubation was performed in one step, for 48 
hours at 37°C. Deglycosylated proteins were denatured with 
reducing Laemmli sample buffer at 97°C for 5 minutes, sepa-
rated by SDS-PAGE using 4% to 12% Bis-Tris gels (Invitrogen), 
transferred to nitrocellulose membranes (GE Healthcare), and 
subjected to immunoblotting following standard protocols. 
The following primary antibodies were used: MFAP4 (Abcam, 
ab169757), ACAN (aggrecan) neoepitope (Thermo Fisher 
Scientific, PA1-1746), VCAN (versican) neoepitope (Abcam, 
ab19345), and TGF-β1 (Abcam, ab179695) (please see the 
Major Resources Table in the online-only Data Supplement). 
Primary antibodies were detected by anti-rabbit light-chain 
specific secondary antibodies linked to horseradish peroxidase 
(Jackson ImmunoResearch Europe Ltd, 211-032-171). Protein 
bands were detected by enhanced chemiluminescence (GE 
Healthcare) on an x-ray film. The film was scanned and quanti-
fied using Image Quant TL (version 8.1, GE Healthcare).
SMC Culture With TGF-β1
Primary human aortic SMCs (PromoCell, C-12533, 3 dif-
ferent donors, see Major Resources Table in the online-only 
Data Supplement) were cultured in DMEM with 2 mmol/L 
L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, 
and 20% fetal bovine serum. Murine aortic SMCs were cul-
tured similarly, yet with DMEM/F12, from wild-type C57Bl6/J 
aortas after enzymatic digestion as described previously.25 Cell 
experiments were initiated with a subconfluent SMC layer at 
passage 6 to 10. SMCs were preincubated with serum-free 
medium for 24 hours, followed by a 24-hour incubation with 
10 ng/mL recombinant TGF-β1 (R&D, 240-B-002) with or 
without 10 µmol/L of the ALKi (activin receptor-like kinase 
4,5,7 inhibitor) SB 431542 (R&D, 1614) to block TGF-β type 
I receptors. Independent culture experiments were performed 
and normalized to the controls (no TGF-β1 and no ALKi) for 
comparison of fold change after TGF-β1 or simultaneous TGF-
β1 and ALKi treatment.
Silencing of MFAP4 in Human Aortic SMCs
Human aortic SMCs (PromoCell, C-12533, 3 different donors) 
were cultured on 6-well plates (1.5×105 cells/well) using SMC 
Growth Medium 2 (PromoCell C-22062) until 70% confluent. 
MFAP4 siRNA (50 nmol/L, Life Technologies, AM16708, Assay 
ID: 11386) and control siRNA (50 nmol/L, Life Technologies, 
AM4613) were transfected by using lipofectamine in differ-
ent passages of different donors (2 for donor 1, 7 for donor 2, 
and 5 for donor 3) for 6 hours and subsequently in M199 with 
100 U/mL penicillin, 100 µg/mL streptomycin, and 2.5% fetal 
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bovine serum overnight. After replaced with complete medium 
(M199 with 100 U/mL penicillin, 100 µg/mL streptomycin, 
and 20% fetal bovine serum) and cultured for 48 hours, the 
cells were washed using M199 3 times, and further cultured in 
M199 for 24 hours. The cells were harvested for RNA extrac-
tion as detailed below. In total, 14 individual experiments using 
3 different cell lines were performed for each condition. The 
experiment was repeated with a different MFAP4 siRNA at a 
lower concentration (25 nmol/L, Life Technologies, 4392420, 
Assay ID: s8716).
Correction of FBN1 in Induced Pluripotent Stem 
Cell-SMCs From a Patient With MFS
Dermal fibroblasts from a patient with MFS (Coriell Institute, 
GM21943) were reprogrammed into human induced pluripo-
tent stem cells (iPSCs), and the mutation was corrected by 
CRISPR-Cas9 to generate an isogenic control.26 Control and 
Marfan iPSCs were grown on Vitronectin XF (STEMCELL 
Technologies) and maintained in mTeSR E8 media (STEMCELL 
Technologies). They were then differentiated into neural crest 
SMCs using the methods described previously.27,28 After dif-
ferentiation, the resulting SMCs were maintained in DMEM 
supplemented with 10% fetal bovine serum for at least 2 
weeks before seeding onto UniFlex Culture Plates (FlexCell 
International Corporation). After 4 days, the SMCs were 
stretched for 48 hours using a Cyclic Stress Unit (FX5000 
Tension System, FlexCell International Corporation), using a 
cyclic sine wave (60 cycles/min) and 10% elongation.
Gene Expression Analysis
Total RNA was isolated from aortic tissues (n=5 for control 
group and n=11 for MFS group), human aortic SMCs from the 
TGF-β1 experiment (3 different donors with 6 technical repli-
cates for control, TGF-β1, and TGF-β1+ALKi groups), human 
aortic SMCs from the siRNA experiment (3 different donors 
with 14 technical replicates for both control siRNA and MFAP4 
siRNA group) and iPSC-SMCs using the miRNeasy Mini kit 
(Qiagen) as described previously.29 Briefly, 700 µL of QIAzol 
reagent was added to samples. A homogenization step in a 
Precellys 24-Dual homogenizer (Peqlab) using Lysing Matrix 
D ceramic beads (MP Biomedicals) was performed for tissues 
only. After a brief incubation at room temperature, 140 µL of 
chloroform was added, and the solution was mixed vigorously. 
The samples were then centrifuged at 16000g for 15 minutes 
at 4°C. The aqueous phase was carefully transferred to a new 
tube and mixed with 1.5 volumes of 100% ethanol. The sam-
ples were then applied directly to columns and washed accord-
ing to the manufacturer’s instructions. Total RNA was eluted 
in 25 µL of nuclease-free H2O. RNA was reverse-transcribed 
into cDNA using the High Capacity Reverse Transcriptase kit 
(Life Technologies). Quantitative polymerase chain reaction 
(qPCR) was performed using Taqman Assays to assess the 
gene expression levels with GAPDH as a normalization control.
For experiments concerning TGF-β1 stimulation of mouse 
aortic SMCs, RNA was isolated from SMCs with the Aurumn 
total RNA mini kit (BioRad) according to the manufacturer’s 
instructions. cDNA synthesis was performed with the iScript 
cDNA synthesis kit (BioRad). Specific primers were designed 
using Primer3 to analyze MFAP4 gene expression. The 60S 
acidic ribosomal protein P0 (Rplp0) gene was used for nor-
malization. Quantitative real-time PCR was performed on a 
LightCycler 480 system (Roche) using the SensiFAST SYBR 
No-ROX Kit (Bioline). All primers used for qPCR analysis 
are listed in Major Resources Tables in the online-only Data 
Supplement.
Histological Analysis and 
Immunohistochemistry
Alcian blue staining was performed in aortic tissues from 
patients with MFS (n=27) and controls (n=7) to visualize acidic 
polysaccharide accumulation, such as glycosaminoglycans and 
quantified (corrected for medial area) with QWin software (ver-
sion 3.0, Leica Microsystem). Nuclear Fast red was used as 
counterstain for nuclei. Immunohistochemistry was performed 
on 7 µm thick formalin-fixed paraffin embedded aortic tissue 
sections from patients with MFS. Sections were first deparaf-
finized in xylene followed by rehydration. To quench the endog-
enous peroxidases, sections were treated with 2% hydrogen 
peroxide for 20 minutes, followed by a 30 minutes incubation 
with 10% normal goat serum and 1% bovine serum albumin 
diluted in Tris-buffered saline to block nonspecific binding. The 
sections were then incubated overnight at 4°C with a polyclonal 
rabbit anti-MFAP4 antibody (Abcam, ab80319) diluted 1:500 
in Tris-buffered saline. Control sections were treated with rab-
bit IgG. The following day the slides were incubated for 30 
minutes with an horseradish peroxidase-conjugated anti-rabbit 
immunoglobulin polymer (Immunologic) diluted 1:1 with Tris-
buffered saline followed by development with bright 3,3′-diami-
nobenzidine (Immunologic). The sections were counterstained 
with Gill’s hematoxylin and mounted with Pertex.
MFAP4 Quantification in Plasma Samples From 
Patients With MFS
For the analysis of plasma protein levels of MFAP4, we used the 
same samples as described earlier (n=96).21 A human MFAP4 
ELISA kit (Elabscience, E-EL-H0581) was used to determine 
MFAP4 protein levels in plasma following the manufacturer’s 
instructions. Briefly, plasma samples from patients with MFS 
were diluted 1:50 with the standard and sample diluent pro-
vided. The samples were incubated for 90 minutes at 37°C in 
the provided wells coated with anti-MFAP4 antibody. Second, 
the samples were removed followed by a 1-hour incubation 
at 37°C with the anti-MFAP4 biotinylated detection antibody. 
After washing, a 30 minutes incubation with an horseradish 
peroxidase conjugate was followed by another washing step. 
Last, a horseradish peroxidase substrate was added for 5 min-
utes with subsequent addition of the stop solution. Optical den-
sity was measured at a wavelength of 450 nm with the ELx808 
ultra microplate reader (BioTek Instruments, Inc, Winooski, VT).
Ultrasonic and MRI Measurements of the Aorta
In the COMPARE patients, the aortic root diameter was mea-
sured at time of inclusion and during follow-up yearly by echo-
cardiography. The aortic growth rate (mm/y) was determined 
after 38 months of follow-up, by subtracting the root diameter 
at baseline from the most recent diameter, dividing this by the 
COMPARE follow-up period in years. Occurrence of events, 
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such as prophylactic aortic surgery or aortic dissection, were 
recorded during the follow-up of 68 months. Aortic distensi-
bility at 4 levels throughout the aorta was calculated: (1) the 
ascending aorta, (2) the descending thoracic aorta at the level 
of the bifurcation of the pulmonary artery, (3) the descending 
aorta at the level of the diaphragm, and (4) the abdominal aorta 
just above the bifurcation. Measurements were performed by a 
single analyst using cine magnetic resonance images, as previ-
ously described.5,21,30
Statistical Analysis
Continuous data are presented as mean with SD or median 
with range, as described in the figure legends. Categorical vari-
ables were summarized using proportions.
The quantities of the proteins/peptides were scaled using 
log2 transformation. The data sets were further filtered to keep 
only measurements with <30% missing values or with >90% 
missing values one of the examined conditions and <10% for 
the rest of the conditions. In the latter case, missing values of 
the condition which presented >90% of missing values were 
imputed with zeros. All remaining missing values were imputed 
with KNN-Impute method with k equal to the minimum among 
20 and the sample size of the phenotype with the fewest 
samples.
Before performing statistical comparison, we performed the 
Shapiro-Wilk normality test to check whether the relative quan-
tities were normally distributed.
For continuous variables with a normal distribution, differ-
ences between groups were analyzed with a Student t test. 
When the data were not normally distributed, nonparamet-
ric methods were used. In specific, for paired comparisons, 
the Wilcoxon signed-rank test and Mann-Whitney U test for 
unpaired comparisons were used. P values were adjusted using 
the Benjamini-Hochberg method, and a threshold of 0.05 was 
used for the adjusted P values to infer statistically significant 
changes.
Differences in categorical variables were analyzed with a 
χ2 or Fisher Exact test. The Kaplan-Meier analysis was used 
for comparisons of event-free survival. Statistical analysis was 
performed using SPSS software (version 24.0, IBM) or Python 
(version 3.7.2) scripts. Graphs were created with Graphpad 
Prism software (version 7.04).
RESULTS
Glycoproteomics of the Aortic ECM in Patients 
With MFS
Enhanced glycoprotein levels in the aorta of patients with 
MFS were demonstrated by Alcian blue staining, com-
pared with aneurysmal patients without MFS (Figure 1A). 
For glycoproteomics, thoracic aortic aneurysm samples 
from patients with and without MFS (n=11 and n=6, 
respectively, Table I in the online-only Data Supplement) 
Figure 1. Glycoprotein content in aneurysms of patients with Marfan syndrome (MFS).  
A, Alcian blue staining of aortic tissue sections from patients with MFS (n=27) and controls (n=7). Stronger blue staining indicates buildup of 
glycoproteins as well as mucopolysaccharides. Scale bars are 50µm. *P<0.05 by Student t test. B, Glycoproteomics workflow showing the 
3-step extraction, enrichment and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of extracellular matrix (ECM)-derived 
glycopeptides from thoracic aortic aneurysm tissue of control (n=6) and MFS patients (n=11). ETD indicates electron transfer dissociation; and 
HCD, higher-energy collisional dissociation; RT, retention time; and SDS, sodium dodecyl sulphate.
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were compared. The ECM was extracted using our 3-step 
extraction protocol. The glycopeptides in the GuHCl frac-
tion were enriched and analyzed by a glycoproteomic 
approach on an Orbitrap Elite MS (Figure 1B). After man-
ual validation of the identified glycopeptides, a total of 
215 unique spectra, corresponding to 35 different glyco-
proteins, were confirmed. A total of 141 glycoforms on 47 
glycosites were identified (Table III in the online-only Data 
Supplement). Among these, 119 unique spectra were 
deemed suitable for further quantitative analysis using 
their precursor peak area. In total, 38 N-linked glycopep-
tides from 8 ECM proteins were differentially expressed. 
The most significant differences between MFS and non-
MFS were observed for MFAP4, as well as for the 2 
large aggregating proteoglycans PGCA (aggrecan) and 
CSPG2 (versican; Figure 2A, Table IV in the online-only 
Data Supplement). MFAP4 has 2 N-glycosites at aspar-
agine (N) positions N87 and N137. Interestingly, only 5 
glycoforms were identified at N87 compared with 21 
glycoforms at N137. Compared with all other identified 
glycoproteins, MFAP4 exhibited the greatest number of 
unique glycoforms overall (Figure 2B).
Glycan Heterogeneity of MFAP4
Next, we focused on the glycoform diversity present at 
the 2 glycosites of MFAP4. Representative MS/MS 
spectra from glycopeptides derived from the N87 and 
N137 sites are provided (Figure I in the online-only Data 
Supplement). We discovered that glycopeptides corre-
sponding to both glycosites displayed significantly higher 
abundance in the aortic ECM of MFS patients compared 
to non-MFS controls (Figure 3A). Notably, glycans linked 
to N87 all belonged to the high-mannose class. Of these, 
glycopeptides consisting of 8 to 10 monosaccharides 
were increased in samples from patients with MFS while 
no significant changes were observed for glycopeptides 
with 6 or 7 monosaccharides (Figure 3B). More diverse 
glycans were attached to the N137 glycosite. Contrary to 
N87, only one out of 13 glycans was high-mannose, and 
the corresponding glycopeptide was increased in patients 
with MFS. All other glycans were of a hybrid/complex 
class, of which 11 corresponding glycopeptides were sig-
nificantly increased in patients with MFS (Figure 3C).
MFAP4 Gene Expression in Patients With MFS
To complement the proteomics data, we determined the 
corresponding levels of gene expression for a select 
panel of ECM proteins. From a subset of the same aortic 
specimens used for glycoproteomics analysis (n=5 for 
control group and n=11 for MFS group), the mRNA lev-
els of 55 ECM protein genes were quantified by qPCR. 
The mRNA levels of several elastin fiber-related proteins 
were significantly higher in MFS patients compared with 
controls, including fibulin-5 (FBLN5), latent-transform-
ing growth factor-β-binding protein 1 (LTBP1), and 4 
(LTBP4) as well as MFAP4 (Figure 4A, Table V in the 
online-only Data Supplement).
MFAP4 in Patients With BAV
The presence of a BAV is a predisposing factor for the 
development of thoracic aortic aneurysms.31 To explore 
Figure 2. Glycoproteomic analysis of the aortic extracellular matrix (ECM) in aneurysms of patients with Marfan syndrome 
(MFS).  
A, Volcano plot showing the difference in abundance of glycopeptides derived from ECM proteins in thoracic aneurysms of MFS vs control 
patients. Versican (CSPG2), MFAP4 (microfibril-associated glycoprotein 4), and PGCA (aggrecan) have been highlighted with their 
accompanying glycosylation sites. Different data points for the same color represent alternative glycans at the same glycosylation site. Mann-
Whitney U tests were used with multiple testing adjustment. Thresholds for significance are indicated by dotted lines (P<0.05 and fold change 
<0.5 or >2). B, All identified glycoproteins are plotted according to their number of unique glycosites and number of unique glycoforms. 
MFAP4 possesses the highest number of unique glycoforms.
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whether MFAP4 may be upregulated in early stages of 
this disease, we obtained aortic specimens from patients 
with BAV not presenting with aortic aneurysms (Table II 
in the online-only Data Supplement). Using proteomics, 
we compared the ECM of the convex and concave area 
within the same nonaneurysmal aortas (n=8). The con-
vex area of the ascending aorta is more prone to aneu-
rysmal development, most likely because of shear stress 
exposure, which is altered in BAV patients compared 
with individuals with TAV.32 Interestingly, we found that 
although no aortic aneurysms were present, the abun-
dance of MFAP4 protein was higher in the convex area 
when analyzed by LC-MS/MS. Notably, the increase in 
MFAP4 was accompanied by a rise in FBN1 (Figure 4B, 
Table VI in the online-only Data Supplement). MFAP4 
and FBN1 were validated by a targeted multiple reac-
tion monitoring method in GuHCl fraction of concave and 
convex samples of aortas from both nonaneurysmal BAV 
patients and nonaneurysmal TAV patients (n=7). These 2 
proteins were significantly increased (MFAP4: 1.54-fold 
increase, P=0.025; FBN1: 1.67-fold increase, P=0.029) 
in the convex area of BAV patients compared to the 
concave area, but this was not the case in TAV patients 
(MFAP4: 1.35-fold increase, P=0.231; FBN1: 2.19-fold 
increase, P=0.075; Figure II and Table VII in the online-
only Data Supplement).
MFAP4, Proteoglycans, and ADAMTS Proteases 
in MFS
Using an N-terminal antibody for MFAP4, we confirmed 
an increase in MFAP4 levels in the NaCl fraction (Fig-
ure 4C) but not in the GuHCl fraction (Figure 4D) of MFS 
aortic tissue. Alongside MFAP4, the large aggregating 
proteoglycans CSPG2 and PGCA were increased in the 
glycopeptide analysis without corresponding changes in 
gene expression. Large aggregating proteoglycans are 
cleaved by members of the ADAMTS (a disintegrin and 
metalloproteinase with thrombospondin motifs) fam-
ily. Two anti-neoepitope antibodies were used to detect 
ADAMTS-specific cleavage of aggrecan and versican 
in MFS: the aggrecan neoepitope antibody detects the 
neoepitope sequence NITEGE, generated by ADAMTS-
cleavage at the position Glu392-Ala393 in the core 
Figure 3. Increased MFAP4 (microfibril-associated glycoprotein 4) glycopeptides in patients with Marfan syndrome (MFS). 
A, Quantification of the overall glycopeptide abundance on the 2 MFAP4 glycosites between MFS and control groups. B, Quantification of 
glycopeptides with different high-mannose glycans on N87 of MFAP4. C, Quantification of glycopeptides with different glycans on N137. Box 
and whisker plots represent the second and third quartiles and error bars expand from the 10th to the 90th percentiles. Circled data points 
along the x-axis represent no detection (n=6 for control and n=11 for MFS, with duplicate liquid chromatography-tandem mass spectrometry 
[LC-MS/MS] runs for each sample). dHex indicates L-Fucose; Hex, Hexose; HexNAc, N-Acetyl-hexosamine; and NeuAc, N-Acetylneuraminic 
acid. *P<0.05, **P<0.01 by Mann-Whitney U test with multiple testing adjustment using Benjamini-Hochberg method.
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protein; the versican neoepitope antibody detects the 
neoepitope sequence DPEAAE, generated by ADAMTS-
cleavage at the position Glu441-Ala442 of the protein 
core of versican isoform V1.33 Detection of both neoepi-
topes was higher in the GuHCl fraction of patients with 
MFS compared with control but only versican reached 
statistical significance. Interestingly, levels of TGF-β1 
remained unaltered between MFS and control patients 
(Figure III in the online-only Data Supplement).
Regulation of MFAP4 Expression
TGF-β1 has been implicated in the pathophysiology 
of aortic aneurysms in patients with and without MFS, 
via both direct genetic mutations in the TGF-β path-
way (Loeys-Dietz Syndrome) and as a consequence of 
FBN1 mutations (MFS) leading to dysregulated TGF-
β1 levels in the pericellular environment and excessive 
TGF-β1 signaling through ALK receptors. In human and 
murine aortic SMCs, administration of TGF-β1 upregu-
lated MFAP4 gene expression. This effect was reversed 
by the presence of an ALK receptor inhibitor (Figure 5A 
and 5B, Table VIII in the online-only Data Supplement). 
Therefore, TGF-β1 may function as a transcriptional 
regulator of MFAP4 in arterial SMCs and contribute to 
MFAP4 regulation during aortopathy.
Silencing of MFAP4 in Human Aortic SMCs
To investigate the functional consequences of altera-
tions in MFAP4 expression, we used a gene silencing 
approach to inhibit MFAP4 translation in cultured human 
aortic SMCs. Efficient knockdown of MFAP4 (Log2 
fold change =−4.34 compared with control, P=0.004) 
resulted in increased expression of elastin (ELN, Log2 
fold change =2.35, P=0.004) and reduced expression 
of FBN1 (Log2 fold change =−0.50, P=0.005). Interest-
ingly, silencing of MFAP4 also significantly attenuated 
the expression of versican (VCAN, Log2 fold change 
=−0.50, P=0.007), whereas aggrecan (ACAN) expres-
sion was variable between different donors (Figure 5C, 
Figure IV and Table IX in the online-only Data Supple-
ment). We have recently highlighted the importance of 
aggrecan and the ADAMTS family in stent-induced vas-
cular injury.34 Moreover, ADAMTS family members have 
been implicated in murine thoracic aortic aneurysm for-
mation.24,35 To further investigate whether MFAP4 may 
be linked to ADAMTS enzymes, we tested the expres-
sion levels of ADAMTS-1 and -4. While ADAMTS-1 
(Log2 fold change =−0.80, P=0.004) was significantly 
decreased after MFAP4 knockdown, ADAMTS-4 (Log2 
fold change =0.54, P=0.055) appeared to be margin-
ally increased (Figure 5C). Unlike ADAMTS proteases, 
Figure 4. MFAP4 (microfibril-associated glycoprotein 4) expression is upregulated in Marfan syndrome (MFS).  
A, Volcano plot showing the differences in gene expression of selected extracellular matrix (ECM) proteins between aneurysmal thoracic aortic 
tissue from patients with MFS (n=10) and controls (n=5). P values were calculated using Mann-Whitney U test. B, Volcano plot showing the 
ECM protein differences between concave and convex area of the same thoracic aorta from nonaneurysmal BAV patients (n=8). P values were 
calculated using Wilcoxon signed-rank test. Immunoblotting for MFAP4 in the NaCl (C) and guanidine hydrochloride (GuHCl) samples (D) 
between aneurysmal thoracic aortic tissue from patients with MFS (n=10) and controls (n=5). Please note the control sample in lane 1 with 
high MFAP4 in the NaCl fraction is from a patient with a TGFBR1 (transforming growth factor β receptor type 1) mutation. FBN1 indicates 
fibrillin-1. Student t test: *P<0.05.
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the expression of 3 MMPs (matrix metalloproteinases), 
namely MMP2 (collagenase), MMP9 (collagenase), and 
MMP12 (elastase), did not show significant changes in 
response to MFAP4 inhibition (Table IX in the online-only 
Data Supplement).
Induced Pluripotent Stem Cells-Derived SMCs
It is worth noting that apart from MFAP4 other elastic 
fiber-interacting proteins were increased as well in gene 
expression data from MFS aortas, such as FBLN5, LTBP 
1 and 4, and lactadherin (MFGE8; Figure 4A). To further 
Figure 5. Changes of MFAP4 (microfibril-associated glycoprotein 4) in relation to TGF-β1 (transforming growth factor β receptor 
type 1), ELN (elastin), and FBN1 (fibrillin-1).  
MFAP4 gene expression was quantified in human (A) and murine (B) aortic smooth muscle cell (SMCs) after incubation with TGF-β1 in the 
absence or presence of an ALKi (activin-like kinase 4,5,7 inhibitor). Data points are individual replicates with horizontal bars representing the 
average. The dashed line represents the control (no TGF-β1, no ALKi) average, which was set to 1. Log2 fold change (FC) as compared to control 
group. P values were calculated using Student t test. *P<0.05, ***P<0.001 vs TGF-β1 group; #P<0.05, ###P<0.001 vs Control group. C, 
Silencing of MFAP4 by siRNA in human aortic SMCs (from 3 different donors) resulted in mRNA changes of various extracellular matrix (ECM) 
proteins and members of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family. Gene expression was normalized 
to control group (dotted line). Wilcoxon signed-rank test was performed and adjusted P value was calculated. **P<0.01. D, SMCs were 
differentiated from iPSCs (induced pluripotent stem cell) derived from a Marfan syndrome (MFS) patient and the FBN1 mutation was corrected 
by CRISPR/Cas9 (Corr). Cells were cultured under unstretched (US) or stretched (S) conditions. Gene expression was normalized to corrected 
unstretched (Corr US) group (dotted line). In the absence of elastin expression, no changes in MFAP4 were observed. Unpaired Student t test was 
performed and adjusted P value was calculated. *P<0.05, **P<0.01 compared to Corr US group; ##P<0.01 compared to Corr S group.
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investigate the functional links between FBN1, ELN, and 
MFAP4, dermal fibroblasts of a patient with MFS were 
reprogrammed into iPSCs. The FBN1 gene mutation was 
corrected using CRISPR-Cas9 to provide an isogenic 
control.26 Both the FBN1-mutant iPSCs and FBN1-
corrected iPSCs were further differentiated into neural 
crest vascular SMCs.26 Gene expression was assessed 
by qPCR under static and stretch conditions. FBN1 
expression was higher in the SMCs from the patients 
with MFS than in the corrected isogenic control under 
both conditions (P<0.01 for both comparison). As elas-
tin expression was undetectable in these iPSC-derived 
SMCs (Ct >35 cycles), expression levels of MFAP4 were 
unchanged (Figure 5D).
Figure 6. Plasma levels of MFAP4 (microfibril-associated glycoprotein 4) predict the occurrence of type B dissections.  
A, Aortic tissues from patients with Marfan syndrome (MFS) were stained for MFAP4 (red-brown) with hematoxylin (blue) nuclear 
counterstaining. MFAP4 is localized throughout the vessel wall with prominent staining of the internal elastic lamina (arrow), the adventitia and 
the medial layer. Scale bars are 100 µm. B, The distensibility measurements in patients with MFS are shown at the ascending (level 1; n=54 
vs n=25), proximal descending (level 2; n=53 vs n=25), distal descending (level 3; n=53 vs n=25) thoracic aorta and abdominal aorta (level 
4; n=46 vs n=24), according to low (bottom 2 tertiles) vs high (upper tertile) plasma MFAP4 concentrations. Survival curve showing the aortic 
surgery incidence (C) and aortic dissection incidence (D) in the 68-mo follow-up period in MFS patients with low (bottom 2 tertiles; n=64) vs 
high (upper tertile; n=32) plasma MFAP4 levels. High plasma MFAP4 levels were associated with a high dissection incidence. The Kaplan-
Meier analysis was used for comparisons of event-free survival.
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Localization of MFAP4
To determine the localization of MFAP4, we performed 
immunostaining of histological sections from aortas of 
patients with MFS. MFAP4 colocalized with the internal 
elastic lamina in the aortic wall and in the adventitia at 
the external elastic lamina and possibly also with colla-
gen fibrils (Figure 6A).
MFAP4 Plasma Levels Associate With Aortic 
Distensibility and Dissection in MFS
In addition to its expression in the aortic ECM, MFAP4 
was detectable in plasma obtained from a subset of 
patients with MFS from the COMPARE trial (n=96).21 To 
determine whether plasma MFAP4 associates with aor-
tic events, the 96 patients with MFS were subdivided into 
3 equal tertiles (lower, middle, and upper tertile) based 
on their MFAP4 protein levels. Patient demographics 
of each tertile are summarized in Table X in the online-
only Data Supplement. No significant differences were 
observed for sex, age, usage of blood pressure lowering 
agents at time of inclusion or the percentage of patients 
who have undergone prophylactic aortic surgery before 
or during follow-up. Twenty aortic root replacements 
and 5 type B dissections (ie, affecting the descending 
thoracic aorta) occurred during the 68 months follow-
up period. Interestingly, all type B dissections occurred 
in patients from the upper tertile (high plasma MFAP4). 
Because there was no significant difference in plasma 
MFAP4 levels between patients with or without previous 
aortic root replacement, MFAP4 seems to be indepen-
dent from this well-known risk factor for type B dissec-
tions. Moreover, high plasma MFAP4 levels or type B 
dissections were not related to any of the blood pressure 
lowering drugs used.
To study local aorta characteristics, the aortic disten-
sibility, which is a measure for aortic wall elasticity, was 
measured at 4 locations: the ascending aorta (level 1, 
n=79), the descending thoracic aorta at the level of the 
bifurcation of the pulmonary artery (level 2, n=78), the 
descending aorta at the level of the diaphragm (level 3, 
n=78), and the abdominal aorta just above the bifurca-
tion (level 4, n=70). Lower distensibility was observed at 
the proximal (level 2, P=0.053) and the distal (level 3, 
P=0.003) descending thoracic aorta in patients with high 
plasma MFAP4 levels (the upper tertile; Figure 6B, Table 
X in the online-only Data Supplement). These are the 
2 locations where type B dissections occur in patients 
with MFS. While in our previous study high plasma TGF-
β1 correlated to the incidence of prophylactic aortic root 
surgery during follow-up (as surrogate for aortic root 
growth),21 high plasma MFAP4 was not associated with 
prophylactic aortic root surgery (P=0.74, Figure 6C). 
However, it was associated with a reduction in dissec-
tion-free survival in this cohort (P=0.025, Figure 6D).
DISCUSSION
ECM degradation and remodeling are hallmarks of aortic 
aneurysm pathology.36 Previously, we established an extrac-
tion methodology for ECM proteins and performed the first 
ECM proteomic comparison between control human aortas 
and abdominal aortic aneurysms.18,36 To further study the 
involvement of ECM proteins in aortic aneurysm formation, 
we provide a glycoproteomics characterization of MFS, a 
condition strongly associated with premature aortopathy. 
We provide evidence for altered glycosylation of MFAP4, 
a protein involved in elastic fiber assembly. Thus, changes 
in ECM proteins in MFS are not confined to abundance 
only, but involve PTMs, which have been far less studied. 
To substantiate the clinical relevance of MFAP4 in patients 
with MFS, we demonstrate that increased plasma levels of 
MFAP4 associate with reduced aortic distensibility and a 
higher incidence of type B dissection.
Glycosylation of MFAP4 in the Human Aorta
Glycosylation is one of the most prominent and complex 
PTMs. Glycans have the ability to alter the mass, charge, 
and electrophoretic properties of proteins, influencing pro-
tein folding, stability, activity, distribution, targeting, and rec-
ognition.37 Moreover, gain-in-glycosylation mutations have 
been shown to comprise a significant number of pathogenic 
mutations, presenting in pathologies such as MFS.38 Sev-
eral glycopeptides displayed altered levels in patients with 
MFS, the highest number of which were glycopeptides from 
MFAP4. MFAP4 contains 2 N-glycosylation sites and evi-
dence for MFAP4 glycosylation was previously established 
by N-terminal sequencing of the recombinant glycoprotein.39 
The functional impact of MFAP glycosylation changes has 
been suggested previously, since this may result in a more 
negatively charged glycoprotein, which confers a stronger 
electrostatic affinity to positively charged proteins, such as 
tropoelastin.40 A greater negative charge in MFAP4 could 
be achieved on accumulation of sialic acid (NeuAc), the only 
glycan-building monomer bearing a net negative charge.41 
Moreover, the presence of sialic acid is restricted to gly-
cans attached to the N137 position of MFAP4, and the 
majority of corresponding glycopeptides were increased in 
the aortic ECM of MFS patients. Therefore, certain glyco-
forms might be favored at specific glycosylation sites, which 
could underlie a compensatory response that enhances the 
interaction of MFAP4 with elastin fibers during aneurysmal 
development to strengthen the integrity of the vessel wall. 
This concept of adaptive regulation in response to changes 
in elastic fiber content has previously been observed in a 
proteomic analysis of aortic aneurysms.42
MFAP4 in Elastic Fibre Composition
Elastic fiber breakage is a key characteristic of aortopa-
thy, as which occurs in MFS.43 Underlying elastin micro-
fibrils contain FBN1, LTBPs, fibulins, MFAPs, and other 
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microfibril-associated glycoproteins.44 MFAP4 mainly 
localizes at sites rich in elastic fibers and is known to be 
involved in their assembly and maintenance.45 It is note-
worthy that mRNA levels of MFAP4 are higher in MFS 
compared with control patients and also that mRNA lev-
els of ELN were upregulated when MFAP4 knockdown 
was performed in human aortic SMCs. Interestingly, a 
2-fold increase in MFAP4 abundance in the ascending 
aorta of patients with MFS has been previously reported 
using difference in-gel electrophoresis.46 The coordi-
nated expression with FBN1 may be expected, given that 
MFAP4 has been demonstrated to bind and colocalize 
with FBN1 to aid in elastin fiber formation.45 However, 
correction of the FBN1 mutation in iPSC-derived vascu-
lar SMCs had no direct effect on MFAP4 levels, as these 
SMCs produced little elastin in culture. In some iPSC-
derived SMCs with detectable elastin expression (Ct <35 
cycles), however, a corresponding increase in MFAP4 
expression was observed (data not shown). Thus, the 
rise in MFAP4 is a compensatory response to the abnor-
mal elastin formation in patients with MFS rather than a 
direct consequence of the FBN1 mutation. Apart from 
MFAP4, compensatory changes were also observed for 
other elastin accessory proteins at the predilection site 
of nonaneurysmal aortas from BAV patients. While these 
early compensatory mechanisms may transiently improve 
interactions between fiber components, they might con-
stitute defective long-term remodeling of the vascular 
ECM. It is noteworthy that MFAP4 has been shown to 
promote SMC proliferation and migration during vascular 
injury,45,47 supporting the concept that ECM remodeling 
also provides direct signals to cells within the ECM.
MFAP4 and TGF-β1 Signaling
It has been suggested that mutant FBN1 expressed in 
the ECM leads to excessive TGF-β signaling, thereby 
coordinating the pathophysiological sequelae of MFS.48 
This hypothesis has recently been challenged by clinical 
trials showing no superiority of losartan, an angiotensin II 
type 1 receptor antagonist and inhibitor of TGF-β produc-
tion, over or alongside conventional β-blocker therapy.6–8 
In arterial SMCs from humans and mice, TGF-β1 was a 
potent inducer of MFAP4 expression. However, plasma 
TGF-β1 and plasma MFAP4 each predicted different 
aortic events in patients with MFS, suggesting that there 
will be additional inducers of MFAP4 to be discovered. 
In contrast to other studies,49–51 we failed to observe a 
significant change in TGF-β1 protein levels in the aortic 
ECM of patients with MFS versus controls.
MFAP4 and Proteoglycan Turnover
Changes in the large aggregating proteoglycans versi-
can and aggrecan at the glycopeptide level accompanied 
those observed for MFAP4 in patients with MFS. Our 
laboratory has previously highlighted the role of ADAMTS 
proteases in the proteolysis of aggrecan and versican in 
the vasculature.34 In patients with MFS, we observed an 
increase in the ADAMTS-mediated cleavage product of 
versican. This may reflect a buildup of proteoglycan sub-
strate, which has been shown to occur in patients with 
thoracic aortic aneurysm or dissection, including those 
with MFS.52 Notably, our experiments showed for the 
first time that a reduction of MFAP4 in SMCs leads to a 
parallel reduction in the expression of versican, as well 
as several different changes in the ADAMTS enzyme 
family. Changes in ECM may act as signaling mecha-
nisms affecting ADAMTS expression and activity on the 
large aggregating proteoglycans. Reduced expression 
of ADAMTS-1 in mice and humans has previously been 
associated with MFS-related aortopathy,35 but our most 
recent data point towards a greater role for ADAMTS-5, 
at least in mice.25 The contribution of proteoglycans 
and their remodeling to the pathology of MFS in aortas 
will require further investigation, especially since muta-
tions in ADAMTS family members were found to phe-
nocopy genetic disorders caused by mutations affecting 
FBN1.53,54
MFAP4 as Plasma Biomarker for Vascular 
Remodeling
In the present study, we demonstrated that MFAP4 is 
abundant in the aortic vessel wall of patients with MFS 
and that type B dissections occurred during follow-up 
in the patients with high plasma MFAP4. Higher plasma 
MFAP4 levels also associated with a lower descending 
thoracic aorta distensibility. The association of aortic dis-
tensibility of the thoracic descending aorta and type B 
dissections has been made previously.5 It is especially 
interesting that MFAP4 is not associated with prophy-
lactic aortic root surgery, which is a known risk factor for 
type B dissections.  Plasma TGF-β1 levels associate with 
aortic root growth and, therefore, may predict prophylac-
tic aortic root surgery to prevent type A dissections,21 
whereas plasma MFAP4 levels seem related to reduced 
distensibility of the descending aorta and predict the 
probability of a type B dissection. Although these find-
ings await confirmation in larger cohorts, MFAP4 is an 
interesting candidate biomarker to identify patients with 
MFS at higher risk for type B dissection, who could be 
monitored more closely.
Conclusions
The majority of patients with MFS have a greater pro-
pensity to experience thoracic aortic aneurysms and 
dissections. Until now, no in-depth glycoproteomics 
characterization of the vascular ECM in patients with 
MFS has been performed. Our glycoproteomics analysis 
revealed that MFAP4 glycosylation is enhanced in MFS 
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patients with aortic aneurysms compared with aneu-
rysms in patients without MFS. In addition to its altered 
glycosylation profile in MFS, knockdown of MFAP4 
expression in aortic SMCs also had a profound impact on 
the expression of key ECM components such as elastin 
and FBN1 as well as ADAMTS proteases and versican. 
Taken together, our findings reinforce the notion of an 
interplay between elastic fiber-associated proteins and 
large aggregating proteoglycans during aortic pathol-
ogy.55 ECM remodeling is a hallmark of many vascular 
pathologies, and the application of glycoproteomics to 
the analysis of clinical samples provides insights into the 
changes in essential ECM components which occur dur-
ing disease, which may lead to the discovery of novel 
biomarkers and potential therapeutic interventions.
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